ALLO

Disclaimer

This swing trade playbook is crafted by @shaneman007 with assistance from Grok, an AI developed by xAI, using data as of August 28, 2025. Grok aims to provide accurate insights but may make errors. Trading is high-risk; conduct your own research and consult a financial advisor before acting. Past performance does not guarantee future results.

Swing Trade Playbook: Allogene Therapeutics (ALLO) for Monday, July 28, 2025

Hey, swing traders! It’s @shaneman007, dropping a hot playbook for Allogene Therapeutics (ALLO), a biotech penny stock primed for action. If you’re chasing 30–60% returns over 1–3 days like me, ALLO’s momentum and short-squeeze potential make it a must-watch for Monday, July 28, 2025. With Grok’s number-crunching, I’ve got a clear plan to help you score big while keeping risk tight. Let’s roll!

Market Vibe: What’s the Buzz?

The market’s pumped after a US-EU tariff deal on July 27, 2025, lifted futures (Dow +0.36%, S&P 500 +0.34%, Nasdaq +0.46%). Earnings from Visa ($V), Boeing ($BA), and PayPal ($PYPL) are stirring volatility, and the FOMC meeting on July 30 has traders on edge. This risk-on mood is perfect for speculative plays like ALLO!

Why ALLO Rocks for Swing Trading

Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biotech tackling cancer and autoimmune diseases. Its low price and high volatility make it a swing trader’s dream. Here’s the latest scoop (August 28, 2025):

• Price: $1.21 (+3.88%, +$0.05)
• Volume: 5.74M (above 5.10M 30-day avg)
• Market Cap: $267.37M
• Day’s Range: $1.18–$1.27
• 52-Week Range: $0.8621–$3.78
• Next Earnings: October 29, 2025
• News: Q2 2025 beat estimates (-$0.23 vs. -$0.2685/share), $302.6M cash to 2H 2027, ALPHA3 trial advancing, ALLO-329 (autoimmune) with FDA Fast Track.
• Analysts: “Moderate Buy,” $7.56–$8.88 target (525–634% upside).
• Short Interest: 11.02% (24.45M shares), 6.27 days to cover.

Why Trade It?: ALLO’s 3.88% daily and ~17% gain since mid-August, plus 11.02% short interest, scream momentum and squeeze potential. News on trials (ALPHA3, ALLO-329) could spark 20–50% moves, perfect for our 30–60% goal!

Why Swing Traders Love ALLO

ALLO’s low price, biotech volatility, and short-squeeze setup make it ideal for quick, high-reward trades. This playbook gives you clear entries, exits, and risk controls to trade like a pro!

ALLO Swing Trade Plan

This 1–3 day swing trade targets 30–60% returns with >60% probability, starting Monday, July 28, 2025. We’ll ride ALLO’s momentum and watch for catalysts like trial news or X buzz (#ALLO). Check the table below for two setups:

Metric	Breakout Setup	Pullback Setup
Entry Point	$1.25–$1.30	$1.10–$1.15
Exit Point 1	$1.45 (20% return)	$1.30 (13.6% return)
Exit Point 2	$1.60 (28% return)	$1.45 (21.7% return)
Stretch Target	$1.90 (52% return)	$1.66 (44.3% return)
Stop-Loss	$1.10 (12% downside)	$1.00 (12.5% downside)
Risk/Reward Ratio	1.7:1 (Exit 1), 2.3:1 (Exit 2), 4.3:1 (Stretch)	1.1:1 (Exit 1), 1.7:1 (Exit 2), 3.5:1 (Stretch)
Probability	65% (Exit 1), 55% (Exit 2), 40% (Stretch)	70% (Exit 1), 60% (Exit 2), 45% (Stretch)
Weighted Return	13% (65% × 20%)	9.5% (70% × 13.6%)

Breakout vs. Pullback

• Breakout: Buy above $1.30 with volume >600K shares for fast 20–52% gains. Ideal for aggressive traders chasing momentum.
• Pullback: Buy a dip to $1.10–$1.15 if support holds. Safer, with 70% chance of hitting $1.30, perfect for cautious swings.

Monday Morning Action Plan

ALLO’s momentum makes it a top watch for Monday. Here’s how to trade it:

1. Pre-Market (7:00–9:30 AM EDT): Check movers on Investing.com or MarketBeat. Look for volume >600K or price above $1.30.
2. News & Buzz: Scan X (#ALLO) for retail sentiment and BioPharma Dive for trial news (ALPHA3, ALLO-329).
3. Trade It:
   • Breakout: Enter $1.25–$1.30 on volume >600K. Target $1.45 (20%) or $1.60 (28%), stop at $1.10.
   • Pullback: Buy $1.10–$1.15 if volume >400K. Target $1.30–$1.45, stop at $1.00.
   • Stretch: Hold for $1.90 (52%) if news or a short squeeze (11.02% short interest) hits.
4. Alerts: Set TradingView alerts at $1.30 (entry), $1.45/$1.60/$1.90 (exits), $1.10/$1.00 (stops). Exit early if RSI >70.
5. Risk Control: Size at 1–2% of your portfolio ($1,000–$2,000 on $100K) to cap losses at ~$120.

Early Week Watch (July 28–30)

Keep ALLO on your radar:

• Tuesday (July 29): Earnings from $V, $BA, $PYPL could boost biotech sentiment. If ALLO holds $1.10, target $1.66 (44.3%).
• FOMC (July 30): Low beta (0.36) limits rate impact, but a dovish Fed could lift speculative names.
• Catalysts: Trial news or partnerships could drive 20–50% pops. Check GlobeNewswire.
• Short Squeeze: 11.02% short interest could spark a move if X buzz (#ALLO) spikes. Monitor Ortex.

Risks to Know

• Downside: ~12% loss if stops hit ($1.10/$1.00). Use tight stops to stay safe.
• Volatility: 12% weekly swings mean quick losses without news. Biotech risks (e.g., trial setbacks) could hit hard.
• Liquidity: 5.74M volume is solid, but pre-market spreads may widen. Keep positions small.

Pro Tip

Join me on X (@shaneman007) for real-time ALLO updates and #ALLO buzz. Stay ahead of the crowd with sentiment checks!

Let’s Crush It!

ALLO’s momentum, short-squeeze potential, and biotech volatility make it a killer swing trade for Monday. With 20–52% returns and tight risk controls, this playbook’s built for you to score big. Big thanks to Grok for the analysis—now let’s trade smart! Hit me up on X (@shaneman007) with your ALLO plays!